MedX Announces Intention to Seek Acceptance for Amendment to Warrants

MISSISSAUGA, Ontario--()--MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) is pleased to announce that it is making an Application to the TSX Venture Exchange for Acceptance of the proposed amendment to the terms of 17,495,472 share purchase warrants (“Warrants”) issued in April, May, and July 2020 in connection with Private Placements completed at that time. Pursuant to Acceptance by the TSXV during 2022, the Expiration date of the Warrants was extended to December 31, 2023. Subject to, and conditional on Acceptance by the TSXV, the Company will amend the Exercise Price of the Warrants from $0.20 to $0.14. Each of the Warrants is exercisable to purchase one common share from the Treasury of MedX.

About MedX Health Corp.

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. Visit www.medxhealth.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.

Contacts

Bill Mitoulas, Investor Relations
MedX Health Corp.
bill@medxhealth.com
+1-416-479-9547

Release Summary

MedX Health announces its intention to seek acceptance for an amendment to terms for warrants issued in connection with 2020 private placements.

$Cashtags

Contacts

Bill Mitoulas, Investor Relations
MedX Health Corp.
bill@medxhealth.com
+1-416-479-9547